rethinkTHC Search
Menu
Study breakdown

Preclinical Studies Support CBD for Cognitive Impairment, but Human Evidence Is Still Missing

Narrative ReviewPreliminary evidence
The takeaway

A narrative review found preclinical studies consistently support CBD improving cognition, but clinical human evidence has not yet confirmed these effects.

Cognitive disorder researchers, CBD consumers, neurologists.

Animal studies support CBD for cognition, but human trials have not confirmed it

What the researchers found

Preclinical studies demonstrated CBD improved cognitive performance in animal models of schizophrenia, epilepsy, Alzheimer's, and others. Clinical studies have not found consistent evidence. More research is needed.

Why it matters

Cognitive impairment is a major component of many disorders and is often treatment-resistant. The failure to translate animal CBD findings to humans is a critical gap.

The numbers in context

Preclinical evidence positive across multiple disease models. Clinical evidence not consistently supportive.

How the study worked

Narrative review evaluating preclinical and clinical data on CBD for cognitive impairment across multiple disorders.

What this study cannot tell us

Narrative review without meta-analysis. Limited clinical studies. Varying assessment tools and doses.

How to read the evidence

Narrative review highlighting a clear translational gap.

When this study was published

Published 2023.

The bigger picture

The translation gap between animal and human CBD studies is a recurring theme in cannabinoid research.

Questions still open

  • Are current clinical trial designs adequate to detect CBD cognitive effects?
  • Would chronic CBD show cognitive benefits that acute dosing does not?

Common questions

Can CBD improve cognitive function?
Animal studies suggest it can, but human trials have not confirmed cognitive benefits.
What conditions were studied?
Schizophrenia, epilepsy, Alzheimer's disease, and other conditions.

Read the original research

Use of cannabidiol (CBD) for the treatment of cognitive impairment in psychiatric and neurological illness: A narrative review.

Experimental and clinical psychopharmacology, 31(5), 978-988

Citation

Ortiz, Rachel; Rueda, Sergio; Di Ciano, Patricia. (2023). Use of cannabidiol (CBD) for the treatment of cognitive impairment in psychiatric and neurological illness: A narrative review.. Experimental and clinical psychopharmacology, 31(5), 978-988. https://doi.org/10.1037/pha0000659

Explore the wider topic